Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Lung Cancer

Lung Cancer

46 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Lung Cancer

318 trials tracked for Lung Cancer: 35 in phase 3 or 4 and 12 with published results. The most-cited published study has 1683 citations.

318Trials tracked
35Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 4 4 Phase 3 31 Phase 2 165 Phase 1 13 Other / NA 105
  1. Phase 3 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Completed · 1,683 cited
  2. Phase 3 ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Completed · 990 cited
  3. Phase 3 High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed · 590 cited
  4. Phase 3 An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy Completed · 271 cited
  5. Phase 3 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) Completed · 221 cited
  6. Phase 3 Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer Completed · 116 cited
Show 44 more trials
  1. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 113 cited
  2. Phase 3 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed · 108 cited
  3. Phase 4 An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Completed · 79 cited
  4. Phase 3 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Completed · 76 cited
  5. Phase 3 PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers Completed · 16 cited
  6. Phase 3 Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC Completed · 11 cited
  7. Phase 4 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed
  8. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  9. Phase 3 Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer Completed
  10. Phase 3 Iressa Follow-up Trial Completed
  11. Phase 3 Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer Completed
  12. Phase 3 A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks Completed
  13. Phase 3 ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting Completed
  14. Phase 3 T790M Plasma Testing Methodology Comparison and Clinical Validation Completed
  15. Phase 3 A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia Completed
  16. Phase 3 A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Completed
  17. Phase 3 Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer Completed
  18. Phase 3 Bintrafusp Alfa Program Rollover Study Completed
  19. Phase 3 Evaluation of the Bio-Seal Biopsy Track Plug Completed
  20. Phase 3 PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer Completed
  21. Phase 3 National Lung Screening Trial (NLST) Screening Completed
  22. Phase 3 Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients Completed
  23. Phase 3 Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer Completed
  24. Phase 3 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer Completed
  25. Phase 3 Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients Completed
  26. Phase 3 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed
  27. Phase 3 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Completed
  28. Phase 3 Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed
  29. Phase 3 Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Completed
  30. Phase 2 Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC) Completed
  31. Phase 2 Study of Arsenic Trioxide in Small Cell Lung Cancer Completed
  32. Phase 2 Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions Completed
  33. Phase 2 BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC Completed
  34. Phase 2 Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Completed
  35. Phase 2 Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer Completed
  36. Phase 2 Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed
  37. Phase 2 Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed
  38. Phase 2 Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC Completed
  39. Phase 2 Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer Completed
  40. Phase 2 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Completed
  41. Phase 2 Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy Completed
  42. Phase 2 BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed
  43. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  44. Phase 2 Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed

Showing the 50 most-cited and recently-updated of 318 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Lung Cancer: what the trials found

Brigatinib demonstrated statistically significant improvements in progression-free survival (PFS) and confirmed objective response rates (ORR) compared to other cohorts 13. Specifically, Brigatinib showed a significant improvement in intracranial ORR 13.

Radiation therapy was associated with significant differences in neurocognitive progression at 3 months, as well as significant differences in local and distant tumor control at 3 months 12.

Cetuximab showed a statistically significant improvement in overall survival (OS) compared to other cohorts 14.

Vorinostat showed a statistically significant improvement in progression-free survival (PFS) 16.

Recent results — preliminary, needs further review

  • * VGT-309 was associated with a statistically significant reduction in Clinically Significant Events (p=<.0001) 1. * Clinical trials are investigating various supportive and diagnostic interventions including Virtual Navigation Systems 2, CBCT Imaging 3, BioSpy System 5, MyLungHealth 6, and Transportation 7. * One fraction stereotactic body radiotherapy is under investigation 4.

For the clinician treating this condition

  • Brigatinib is associated with superior progression-free survival and intracranial response rates 13.
  • Radiation therapy impacts neurocognitive status and tumor control metrics 12.
  • Cetuximab is associated with improved overall survival 14.
  • Vorinostat is associated with improved progression-free survival 16.

AI synthesis of 11 cited trials, updated Sep 9, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
ANCA-associated vasculitis doubles lung cancer risk, meta-analysis finds
Pulmonology & Critical Care Meta-analysis
ANCA-associated vasculitis doubles lung cancer risk, meta-analysis finds Lung Cancer Risk Doubles in Patients with ANCA Vasculitis
This meta-analysis of 8004 patients with ANCA-associated vasculitis (AAV) found a 2-fold increased risk of lung cancer (RR 2.08, 95% CI 1.52…
A large meta-analysis finds that people with ANCA-associated vasculitis have about double the risk of lung cancer compared to the general po…
Sep 2, 2026
Statin use is associated with improved overall survival and progression-free survival in lung cancer
Allergy & Immunology Meta-analysis
Statin use is associated with improved overall survival and progression-free survival in lung cancer Statin use linked to better survival in lung cancer patients
This meta-analysis of 5,156 patients found that statin use was associated with significantly improved overall survival (HR = 0.76) and progr…
New data suggests that patients taking statins may live longer and stay cancer-free longer while undergoing specific lung cancer treatments.
Frontiers Sep 2, 2026
Viral hepatitis infections pose significantly higher risk for liver cancer than smoking-related lung cancer
Oncology Meta-analysis
Viral hepatitis infections pose significantly higher risk for liver cancer than smoking-related lung cancer Comparing the risks of liver cancer from hepatitis versus lung cancer from smoking
This meta-analysis of 86,097,714 participants analyzed the relative risks of liver cancer from various exposures compared to lung cancer fro…
New data shows that certain hepatitis viruses pose a much higher risk for liver cancer than smoking does for lung cancer.
Sep 2, 2026
Tailored Physical Activity Programs Improve Functional Capacity and Symptoms in Lung Cancer Patients
Pulmonology & Critical Care Meta-analysis
Tailored Physical Activity Programs Improve Functional Capacity and Symptoms in Lung Cancer Patients Patient-centered physical activity helps manage lung cancer symptoms
Meta-analysis results indicate that personalized exercise programs significantly improve functional capacity and reduce symptoms in lung can…
Tailored exercise programs can improve physical ability and reduce symptoms for people living with lung cancer.
Sep 2, 2026
Critically ill lung cancer patients face 73.5% long-term mortality and 51.9% hospital mortality
Pulmonology & Critical Care Meta-analysis
Critically ill lung cancer patients face 73.5% long-term mortality and 51.9% hospital mortality Data shows lung cancer patients face high long-term mortality rates
This meta-analysis examines mortality outcomes and predictors for critically ill patients with lung cancer. The study finds a 46.4% ICU mort…
Patients with lung cancer in intensive care face high mortality rates, highlighting the need for early and focused goals of care discussions…
Sep 2, 2026
Combined SHOX2 and RASSF1A methylation provides superior diagnostic performance for lung cancer detection
Oncology Meta-analysis
Combined SHOX2 and RASSF1A methylation provides superior diagnostic performance for lung cancer detection Combined Biomarkers Show Better Accuracy for Lung Cancer Diagnosis
This meta-analysis of 49 studies evaluates the diagnostic performance of SHOX2 and RASSF1A methylation in lung cancer. The combined methylat…
Combining two specific genetic markers, SHOX2 and RASSF1A, may provide a more accurate way to detect lung cancer than using either one alone…
Frontiers Aug 30, 2026
TCM nursing improves Karnofsky Performance Status and reduces psychological distress in lung cancer patients
Primary Care & Family Medicine Meta-analysis
TCM nursing improves Karnofsky Performance Status and reduces psychological distress in lung cancer patients Traditional Chinese Medicine Nursing May Improve Lung Cancer Quality of Life
This meta-analysis of 1,135 lung cancer patients indicates that Traditional Chinese Medicine (TCM) nursing significantly improves Karnofsky …
Traditional Chinese Medicine nursing may help lung cancer patients manage pain, anxiety, and depression while improving overall physical per…
Frontiers Aug 30, 2026
mRNA vaccines reshape tumor microenvironment and induce durable anti-tumor immunity in lung cancer
Allergy & Immunology Sys. Review
mRNA vaccines reshape tumor microenvironment and induce durable anti-tumor immunity in lung cancer mRNA Vaccines Show Promise for Lung Cancer Treatment
This systematic review examines the current status and prospects of mRNA vaccines for lung cancer. The authors synthesize evidence that mRNA…
New research explores how mRNA technology can reshape the tumor environment and trigger immune responses to fight lung cancer.
Frontiers Aug 26, 2026
Genetic liability for cannabis use is causally linked to increased risk of esophageal and lung cancers
Genetics & Precision Medicine Meta-analysis
Genetic liability for cannabis use is causally linked to increased risk of esophageal and lung cancers Genetic data reveals link between cannabis use and certain cancers
This meta-analysis using two-sample Mendelian Randomization evaluates the causal link between genetic liability to cannabis use and specific…
New research using genetic markers shows that a person's genetic tendency toward cannabis use may impact risks for lung, esophageal, and pan…
medRxiv Aug 22, 2026
Early activity improves recovery and reduces complications in postoperative patients with lung cancer
Oncology Meta-analysis
Early activity improves recovery and reduces complications in postoperative patients with lung cancer Early activity helps lung cancer patients recover faster after surgery
This meta-analysis of 2,234 patients evaluates early activity for post-surgical lung cancer recovery. The analysis indicates that early acti…
Patients with lung cancer can see shorter hospital stays and fewer complications by starting early physical activity after their surgery.
Frontiers Aug 21, 2026
Combined lung cancer resection and LVRS shows 7.3% mortality estimate with significant FEV1 improvement
Oncology Meta-analysis
Combined lung cancer resection and LVRS shows 7.3% mortality estimate with significant FEV1 improvement Combined lung surgery for cancer and emphysema shows mixed results
This meta-analysis of 113 participants evaluates combined lung cancer resection and lung volume reduction surgery (LVRS) for patients with s…
A combined surgical approach for patients with both lung cancer and emphysema may improve breathing but carries significant risks.
Frontiers Aug 20, 2026
Personalised CT feedback fails to boost quit rates overall in lung cancer screening
Pulmonology & Critical Care RCT
Personalised CT feedback fails to boost quit rates overall in lung cancer screening Personalized images of lung damage do not increase smoking quit rates
In a randomized controlled trial of 1003 individuals attending lung cancer screening, a personalised smoking cessation package with annotate…
Showing patients their own lung scans does not improve overall smoking quit rates, though it may show different results for women.
Aug 15, 2026

Questions about Lung Cancer

How well does osimertinib work for lung cancer patients who have active brain metastasis?

Osimertinib is effective for EGFR-mutated NSCLC patients with active brain metastases, with real-world data showing median progression-free survival of 12.4 months and intracranial responses, though resistance can develop.

Full answer →
Which method is best for placing fiducial markers before radiation for lung cancer?

Endobronchial access has the lowest inaccurate placement rate and low complication risk, making it a strong choice for fiducial marker insertion before lung cancer radiation.

Full answer →
Can a high neutrophil-to-lymphocyte ratio predict if lung cancer will spread to the brain?

Yes, a high neutrophil-to-lymphocyte ratio (NLR) is an independent risk factor for brain metastasis in lung cancer, according to a meta-analysis of 14 studies.

Full answer →
What are the risks of brain metastasis in patients diagnosed with lung cancer?

Brain metastases are common in lung cancer, especially small cell (15% at diagnosis) and non-small cell types, with elevated neutrophil-to-lymphocyte ratio as a risk factor; targeted therapies like osimertinib show high intracranial response rates.

Full answer →

All Lung Cancer Articles